INTERNATIONAL PATENT: GENENTECH, INC., XENCOR, INC. FILES APPLICATION FOR "COMBINATIONS OF IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS AND HER2XCD3 BISPECIFIC ANTIBODIES FOR THE TREATMENT OF HER2-POSITIVE CANCERS"

GENEVA, April 30 -- GENENTECH, INC. (1 DNA WaySouth San Francisco, California 94080-4990), XENCOR, INC. (465 North Halstead Street, Suite 200Pasadena, California 91107) filed a patent application (PCT/US2024/052023) for "COMBINATIONS OF IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS AND HER2XCD3 BISPECIFIC ANTIBODIES FOR THE TREATMENT OF HER2-POSITIVE CANCERS" on Oct 18, 2024. With publication no. WO/2025/085781, the details related to the patent application was published on Apr 24, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): HOLDER, Patrick Gwynn (c/o Genentech, INC.1 DNA WaySouth Sa...